.jpeg)
Oral semaglutide tablets (Semaglutide) launch time
Semaglutide is a glucagon-like peptide 1 (GLP-1) analog used to treat type 2 diabetes and lifestyle changes such as dietary restriction and increased physical activity. Semaglutide tablets were developed by Novo Nordisk and were approved for sale by the U.S. Food and Drug Administration (FDA) in September 2019 under the trade name Rybelsus. The EU was approved for sale in April 2020. Semaglutide tablets have not yet been launched in China, and the specific launch date is unclear. However, its injection has been launched in China and is covered by medical insurance. It can effectively control blood sugar levels in patients with type 2 diabetes.
[ 免责声明 ] 本页面内容来自公开渠道（如FDA官网、Drugs官网、原研药厂官网等），仅供持有医疗专业资质的人员用于医学药学研究参考，不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市，不适用于中国境内销售和使用。如需治疗，请咨询正规医疗机构。本站不提供药品销售或代购服务。
